@article{3106763,
    title = "How I treat rituximab refractory patients with WM",
    author = "Gavriatopoulou, M. and Ntanasis-Stathopoulos, I. and Kastritis, E. and Dimopoulos, M.A.",
    journal = "OncoTargets and therapy",
    year = "2018",
    volume = "9",
    number = "96",
    pages = "36824-36825",
    publisher = "Impact Journals, LLC",
    doi = "10.18632/oncotarget.26411",
    keywords = "acalabrutinib;  beta 2 microglobulin;  Bruton tyrosine kinase;  chemokine receptor CXCR4;  ibrutinib;  immunoglobulin enhancer binding protein;  immunoglobulin M;  interleukin 1 receptor associated kinase 1;  interleukin 1 receptor associated kinase 4;  myeloid differentiation factor 88;  rituximab;  zanubrutinib, aging;  anemia;  apoptosis;  cancer immunotherapy;  cancer prognosis;  correlational study;  CXCR4 gene;  disease course;  drug efficacy;  drug protein binding;  drug resistance;  drug safety;  drug screening;  drug withdrawal;  Editorial;  enzyme activation;  gold standard;  health care cost;  health care quality;  high risk patient;  human;  immunoglobulin blood level;  intensive care;  International Prognostic Scoring System;  lymphocytic infiltration;  monotherapy;  multicenter study (topic);  MYD88 gene;  MYD88L265 gene;  oncogene;  overall survival;  phase 1 clinical trial (topic);  phase 2 clinical trial (topic);  progression free survival;  protein secretion;  randomized controlled trial (topic);  somatic mutation;  toxicity;  treatment duration;  treatment response;  treatment withdrawal;  tumor volume;  Waldenstroem macroglobulinemia"
}